Yahoo Web Search

  1. Ad
    related to Mylan N.V
  1. Should You Buy Mylan (MYL) Ahead of Earnings?

    Zacks via Yahoo FinanceNov 04 13:31 PM

    Investors are always looking for stocks that are poised to beat at earnings season and Mylan N.V. MYL may be one such company. After all, analysts raising estimates right ...

  2. Mylan's (MYL) Q3 Earnings Beat Estimates, Revenues Miss

    Zacks via Yahoo FinanceNov 05 16:41 PM

    Mylan N.V. MYL reported adjusted earnings of $1.17 cents per share in the third quarter of 2019, which beat the Zacks Consensus Estimate of $1.14 but declined from $1.25 ...

  3. Mylan (MYL) to Report Q3 Earnings: What's in the Offing?

    Zacks via Yahoo FinanceOct 30 15:46 PM

    Mylan N.V. MYL is scheduled to report third-quarter 2019 results on Nov 5, before market open. Why a Likely Earnings Beat? Our proven model predicts an earnings beat for ...

  4. Mylan (MYL) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2019. This widely-known consensus outlook ...

  5. Mylan (MYL) Q3 Earnings Surpass Estimates

    Zacks via Yahoo FinanceNov 05 13:25 PM

    Mylan (MYL) came out with quarterly earnings of $1.17 per share, beating the Zacks Consensus Estimate of $1.14 per share. This quarterly report represents an earnings surprise of 2.63% ...

  6. In the last reported quarter, the company beat earnings expectations by 11.07%. It surpassed earnings estimates by average of 6.14% in the last four quarters. For the quarter to be reported, ...

  7. Theravance (TBPH) Q3 Loss In Line, Revenues Lag Estimates

    Zacks via Yahoo FinanceNov 06 16:19 PM

    Total revenues in the third quarter comprised collaboration revenues of $8.8 million and $3.6 million received from Mylan MYL.

  8. On an operational basis, excluding the 2% negative impact of currency, revenues declined 3% year over year as higher sales of some key brands in Pfizer's Biopharmaceuticals group was offset ...

  9. Acorda (ACOR) Q3 Earnings and Revenues Surpass Estimates

    Zacks via Yahoo FinanceNov 05 16:45 PM

    Acorda Therapeutics, Inc. ACOR reported third-quarter 2019 loss per share of 46 cents, narrower than the Zacks Consensus Estimate of a loss of 51 cents. The company generated total revenues ...

  10. GlaxoSmithKline plc GSK reported third-quarter 2019 adjusted earnings of 95 cents per American depositary share, which beat the Zacks Consensus Estimate of 83 cents. Adjusted earnings were up ...

  1. Ad
    related to Mylan N.V